Business Context and Reporting Period
This Form 8-K was filed by Catalyst Biosciences, Inc. (CBIO) on May 19, 2022. The report details a material definitive agreement and the completion of an asset disposition. Note: The request metadata references "Gyre Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Catalyst Biosciences, Inc.
Key Financial Metrics and Transaction Details
The filing reports a specific asset sale transaction rather than standard periodic financial results (revenue, profit, or cash flow).
- Transaction Type: Asset Purchase Agreement with Vertex Pharmaceuticals Incorporated.
- Assets Sold: Catalyst's complement portfolio, including CB 2782-PEG and CB 4332, and related intellectual property (ProTUNE and ImmunoTUNE platforms).
- Total Consideration: $60 million in cash.
- Hold-Back Amount: $5 million retained by the purchaser for one year to satisfy post-closing indemnification obligations.
- Net Immediate Cash Proceeds: $55 million.
Material Changes Versus Prior Period
This filing represents a discrete event rather than a comparative period analysis. The material change is the divestiture of the company's complement portfolio, which alters the company's asset base and future revenue potential from these specific assets. No prior period financial metrics are provided in this document for comparison.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management outlook, or specific risk factors beyond the standard representations and warranties in the Purchase Agreement. The transaction is subject to customary indemnification provisions, with a $5 million hold-back serving as a contingency for post-closing obligations.
Key Facts for Investor Verification
- Verify the exact closing date and the release schedule of the $5 million hold-back amount.
- Confirm the impact of this asset sale on Catalyst's remaining pipeline and future revenue streams.
- Review the full text of the Purchase Agreement (to be filed as an exhibit to the Q2 2022 Form 10-Q) for specific indemnification terms.
- Check subsequent filings for the actual cash receipt and any adjustments to the purchase price.